[1]
Worton R. Muscular dystrophies: diseases of the dystrophin-glycoprotein complex. Science (New York, N.Y.). 1995 Nov 3:270(5237):755-6
[PubMed PMID: 7481760]
[2]
Ervasti JM, Ohlendieck K, Kahl SD, Gaver MG, Campbell KP. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature. 1990 May 24:345(6273):315-9
[PubMed PMID: 2188135]
[3]
Bushby KM, Gardner-Medwin D. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history. Journal of neurology. 1993 Feb:240(2):98-104
[PubMed PMID: 8437027]
[4]
Bellayou H, Hamzi K, Rafai MA, Karkouri M, Slassi I, Azeddoug H, Nadifi S. Duchenne and Becker muscular dystrophy: contribution of a molecular and immunohistochemical analysis in diagnosis in Morocco. Journal of biomedicine & biotechnology. 2009:2009():325210. doi: 10.1155/2009/325210. Epub 2009 May 19
[PubMed PMID: 19461958]
[5]
Straub V, Guglieri M. An update on Becker muscular dystrophy. Current opinion in neurology. 2023 Oct 1:36(5):450-454. doi: 10.1097/WCO.0000000000001191. Epub 2023 Aug 21
[PubMed PMID: 37591308]
Level 3 (low-level) evidence
[6]
Flanigan KM. Duchenne and Becker muscular dystrophies. Neurologic clinics. 2014 Aug:32(3):671-88, viii. doi: 10.1016/j.ncl.2014.05.002. Epub
[PubMed PMID: 25037084]
[7]
Hegde MR, Chin EL, Mulle JG, Okou DT, Warren ST, Zwick ME. Microarray-based mutation detection in the dystrophin gene. Human mutation. 2008 Sep:29(9):1091-9. doi: 10.1002/humu.20831. Epub
[PubMed PMID: 18663755]
[8]
Takeshima Y, Yagi M, Okizuka Y, Awano H, Zhang Z, Yamauchi Y, Nishio H, Matsuo M. Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center. Journal of human genetics. 2010 Jun:55(6):379-88. doi: 10.1038/jhg.2010.49. Epub 2010 May 20
[PubMed PMID: 20485447]
Level 3 (low-level) evidence
[9]
Hoffman EP, Fischbeck KH, Brown RH, Johnson M, Medori R, Loike JD, Harris JB, Waterston R, Brooke M, Specht L. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. The New England journal of medicine. 1988 May 26:318(21):1363-8
[PubMed PMID: 3285207]
[10]
Romitti PA, Zhu Y, Puzhankara S, James KA, Nabukera SK, Zamba GK, Ciafaloni E, Cunniff C, Druschel CM, Mathews KD, Matthews DJ, Meaney FJ, Andrews JG, Conway KM, Fox DJ, Street N, Adams MM, Bolen J, MD STARnet. Prevalence of Duchenne and Becker muscular dystrophies in the United States. Pediatrics. 2015 Mar:135(3):513-21. doi: 10.1542/peds.2014-2044. Epub 2015 Feb 16
[PubMed PMID: 25687144]
[11]
Lin J, Li H, Liao Z, Wang L, Zhang C. Comparison of Carrier and de novo Pathogenic Variants in a Chinese DMD/BMD Cohort. Frontiers in neurology. 2021:12():714677. doi: 10.3389/fneur.2021.714677. Epub 2021 Aug 5
[PubMed PMID: 34421809]
[12]
Aartsma-Rus A, Van Deutekom JC, Fokkema IF, Van Ommen GJ, Den Dunnen JT. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle & nerve. 2006 Aug:34(2):135-44
[PubMed PMID: 16770791]
Level 3 (low-level) evidence
[13]
Fong PY, Turner PR, Denetclaw WF, Steinhardt RA. Increased activity of calcium leak channels in myotubes of Duchenne human and mdx mouse origin. Science (New York, N.Y.). 1990 Nov 2:250(4981):673-6
[PubMed PMID: 2173137]
[14]
Bellinger AM, Reiken S, Carlson C, Mongillo M, Liu X, Rothman L, Matecki S, Lacampagne A, Marks AR. Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Nature medicine. 2009 Mar:15(3):325-30. doi: 10.1038/nm.1916. Epub 2009 Feb 8
[PubMed PMID: 19198614]
[15]
Tidball JG, Villalta SA. NO may prompt calcium leakage in dystrophic muscle. Nature medicine. 2009 Mar:15(3):243-4. doi: 10.1038/nm0309-243. Epub
[PubMed PMID: 19265820]
[16]
Sander M, Chavoshan B, Harris SA, Iannaccone ST, Stull JT, Thomas GD, Victor RG. Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proceedings of the National Academy of Sciences of the United States of America. 2000 Dec 5:97(25):13818-23
[PubMed PMID: 11087833]
[17]
Lai Y, Thomas GD, Yue Y, Yang HT, Li D, Long C, Judge L, Bostick B, Chamberlain JS, Terjung RL, Duan D. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. The Journal of clinical investigation. 2009 Mar:119(3):624-35. doi: 10.1172/JCI36612. Epub 2009 Feb 23
[PubMed PMID: 19229108]
[18]
Kaido M, Arahata K, Hoffman EP, Nonaka I, Sugita H. Muscle histology in Becker muscular dystrophy. Muscle & nerve. 1991 Nov:14(11):1067-73
[PubMed PMID: 1745279]
[19]
Bell CD, Conen PE. Histopathological changes in Duchenne muscular dystrophy. Journal of the neurological sciences. 1968 Nov-Dec:7(3):529-44
[PubMed PMID: 5709861]
[20]
Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, Case LE, Clemens PR, Hadjiyannakis S, Pandya S, Street N, Tomezsko J, Wagner KR, Ward LM, Weber DR, DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. The Lancet. Neurology. 2018 Mar:17(3):251-267. doi: 10.1016/S1474-4422(18)30024-3. Epub 2018 Feb 3
[PubMed PMID: 29395989]
Level 3 (low-level) evidence
[22]
Gatta V, Scarciolla O, Gaspari AR, Palka C, De Angelis MV, Di Muzio A, Guanciali-Franchi P, Calabrese G, Uncini A, Stuppia L. Identification of deletions and duplications of the DMD gene in affected males and carrier females by multiple ligation probe amplification (MLPA). Human genetics. 2005 Jun:117(1):92-8
[PubMed PMID: 15841391]
[23]
Hwa HL, Chang YY, Chen CH, Kao YS, Jong YJ, Chao MC, Ko TM. Multiplex ligation-dependent probe amplification identification of deletions and duplications of the Duchenne muscular dystrophy gene in Taiwanese subjects. Journal of the Formosan Medical Association = Taiwan yi zhi. 2007 May:106(5):339-46
[PubMed PMID: 17561468]
[24]
Leung DG. Magnetic resonance imaging patterns of muscle involvement in genetic muscle diseases: a systematic review. Journal of neurology. 2017 Jul:264(7):1320-1333. doi: 10.1007/s00415-016-8350-6. Epub 2016 Nov 25
[PubMed PMID: 27888415]
Level 1 (high-level) evidence
[25]
Hoffman EP, Kunkel LM, Angelini C, Clarke A, Johnson M, Harris JB. Improved diagnosis of Becker muscular dystrophy by dystrophin testing. Neurology. 1989 Aug:39(8):1011-7
[PubMed PMID: 2668783]
[26]
Ryder S, Leadley RM, Armstrong N, Westwood M, de Kock S, Butt T, Jain M, Kleijnen J. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet journal of rare diseases. 2017 Apr 26:12(1):79. doi: 10.1186/s13023-017-0631-3. Epub 2017 Apr 26
[PubMed PMID: 28446219]
[27]
Yiu EM, Kornberg AJ. Duchenne muscular dystrophy. Journal of paediatrics and child health. 2015 Aug:51(8):759-64. doi: 10.1111/jpc.12868. Epub 2015 Mar 9
[PubMed PMID: 25752877]
[28]
Gloss D, Moxley RT 3rd, Ashwal S, Oskoui M. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016 Feb 2:86(5):465-72. doi: 10.1212/WNL.0000000000002337. Epub
[PubMed PMID: 26833937]
Level 1 (high-level) evidence
[29]
Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscular disorders : NMD. 2006 Apr:16(4):249-55
[PubMed PMID: 16545568]
[30]
Politano L, Nigro G. Treatment of dystrophinopathic cardiomyopathy: review of the literature and personal results. Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology. 2012 May:31(1):24-30
[PubMed PMID: 22655514]
[32]
Hanff E, Hafner P, Bollenbach A, Bonati U, Kayacelebi AA, Fischer D, Tsikas D. Effects of single and combined metformin and L-citrulline supplementation on L-arginine-related pathways in Becker muscular dystrophy patients: possible biochemical and clinical implications. Amino acids. 2018 Oct:50(10):1391-1406. doi: 10.1007/s00726-018-2614-7. Epub 2018 Jul 12
[PubMed PMID: 30003335]
[33]
Elhalag RH, Motawea KR, Talat NE, Rouzan SS, Shah J. Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis. Frontiers in neurology. 2023:14():1107474. doi: 10.3389/fneur.2023.1107474. Epub 2023 Feb 1
[PubMed PMID: 36816559]
Level 1 (high-level) evidence
[34]
Alvarez Leal M, Hernández Sifuentes PM, Pérez-Zuno JA. [Differential diagnosis of Becker and Duchenne muscular dystrophy]. Gaceta medica de Mexico. 1994 Nov-Dec:130(6):454-8
[PubMed PMID: 7557060]
[35]
Furuya T, Tateishi M, Hara M, Kashiwazaki S, Takeuchi M. [Differential diagnosis of Becker-type muscular dystrophy from polymyositis]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine. 1996 Jun 10:85(6):927-9
[PubMed PMID: 8753060]
[36]
Lunt PW, Cumming WJ, Kingston H, Read AP, Mountford RC, Mahon M, Harris R. DNA probes in differential diagnosis of Becker muscular dystrophy and spinal muscular atrophy. Lancet (London, England). 1989 Jan 7:1(8628):46-7
[PubMed PMID: 2563028]
[37]
Norman A, Thomas N, Coakley J, Harper P. Distinction of Becker from limb-girdle muscular dystrophy by means of dystrophin cDNA probes. Lancet (London, England). 1989 Mar 4:1(8636):466-8
[PubMed PMID: 2563842]
[38]
Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. The New England journal of medicine. 1994 Dec 8:331(23):1564-75
[PubMed PMID: 7969328]
[39]
Puckelwartz M, McNally EM. Emery-Dreifuss muscular dystrophy. Handbook of clinical neurology. 2011:101():155-66. doi: 10.1016/B978-0-08-045031-5.00012-8. Epub
[PubMed PMID: 21496632]
[40]
Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet (London, England). 2001 Jun 30:357(9274):2122-8
[PubMed PMID: 11445126]
[41]
Tarnopolsky MA. Metabolic Myopathies. Continuum (Minneapolis, Minn.). 2016 Dec:22(6, Muscle and Neuromuscular Junction Disorders):1829-1851
[PubMed PMID: 27922496]
[42]
Cox GF, Kunkel LM. Dystrophies and heart disease. Current opinion in cardiology. 1997 May:12(3):329-43
[PubMed PMID: 9243091]
Level 3 (low-level) evidence